---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016130"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:57:23.865300+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint

## Summary
- Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.
- Cash and equivalents $597.9M at quarter-end, down from prior quarter but sufficient for operations.
- BEACON study in RVO met primary endpoint: tarcocimab every 8 weeks non-inferior to aflibercept monthly.
- Phase 3 DME studies GLEAM/GLIMMER and wet AMD study DAYLIGHT fully enrolled; topline data expected mid-2023.
- Plans to file single BLA for tarcocimab across all indications if Phase 3 data are positive.

## SEC filing metadata
- accession: 0000950170-22-016130
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/0000950170-22-016130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/kod-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016130
- JSON: https://secwatch.observer/filing/0000950170-22-016130.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.